Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation (Sinopharm), has been dismissed from his role as a delegate to the 14th National People’s Congress due to suspicions of serious disciplinary and legal violations, as determined by the Standing Committee of the National People’s Congress.
A graduate of the Clinical Medicine Department of Lanzhou University School of Medicine, Yang pursued further education in Japan and the United States before returning to China in 2002. He joined Sinopharm’s Wuhan Institute of Biological Products Co., Ltd, where he held various positions including executive deputy director, director, and deputy secretary of the Party Committee. Yang played a pivotal role in the development of domestic pertussis vaccines, expanding production capacity and leading research on various other vaccines, including rotavirus, influenza hemophilus, pneumonia polysaccharide, and multivalent combination vaccines.
In 2010, Yang transitioned to Beijing to take on roles such as president, deputy secretary of the Party Committee, and chairman at Sinopharm. He also directed the National Joint Vaccine Engineering Technology Research Center and served as the chief scientist for the national “863 Program” vaccine project. His leadership contributed to significant research advancements, including the development of Human SARS Immunoglobulin and the SARS Inactivated Vaccine.
Between September 2010 and March 2014, and from October 2016 to December 2022, Yang also served as chairman of Beijing Tiantan Biological Products Co., Ltd, a leading blood products company in China, which became a subsidiary of Sino Bio following two major asset restructurings in 2010 and 2017.
During the COVID-19 pandemic, Yang led his team to develop and commercialize China’s first batch of COVID-19 gene diagnostic kits and the first COVID-19 inactivated vaccine. The Sino Bio COVID-19 gene diagnosis kit was the first recommended by the National Center for Disease Control and Prevention for use in Wuhan Hospital, Hubei Province, and was also the first batch of COVID-19 detection kits approved by the National Medical Products Administration (NMPA). The Sino Bio COVID-19 inactivated vaccine was conditionally approved for marketing by the NMPA in December 2020, marking a significant milestone in China’s fight against the pandemic. For his contributions, Yang Xiaoming was honored as an “exemplary individual in the national fight against COVID-19.”- Flcube.com
